Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : India Coffee House -- Ignore unavailable to you. Want to Upgrade?

To: Mohan Marette who wrote (7136)	9/23/1999 11:15:00 PM
From: Mohan Marette	Read Replies (1) \| Respond to of 12475

Nicholas Piramal & US firm Cytran in advanced human trials for anti-cancer blockbuster Nicholas Piramal--> nicholaspiramal.com Mumbai, Sept 23: Nicholas Piramal, part of the Ajay Piramal group, is conducting advanced human trials on two new chemical entities (NCEs)--an anti-cancer drug (IM862 patented by Cytran of the US) and an anti-infective. Cytran and Nicholas Piramal already have a strategic alliance to develop and market state-of-the-art molecules. Top management officials at Nicholas Piramal said that IM862 is in phase three trials and patents have already been filed in the US. Phase one and phase two trials were done in the US, Europe and Belgium. "We are also refiling for patents in India. The compound could be useful in AIDS too," he said. The US Patent and Trademark Office has granted Cytran Inc a patent for the anti-angiogenesis effects of IM862. The patent covers claims for IM862 to inhibit angiogenesis--the aberrant growth of new blood vessels--in a number of pathological conditions, including malignant tumors, age-related macular degeneration, and vascular diseases. IM862 is a naturally occurring peptide that can be synthesised and manufactured using conventional pharmaceutical peptide technology. Indications are that the marketing rights for the drug, if successful, will be shared between Cytran and Nicholas Piramal, with the latter concentrating on the Asian markets. Cytran has invested around $30-40 million in the project over a period, officials said. Cytran Inc is a privately held biopharmaceutical company, developing and commercialising small peptide compounds for the treatment of cancer and other diseases. The company already holds patents for the immune-modulating effects of IM862, as well as for methods of delivery and pharmaceutical formulations of the drug, in all major world markets...... financialexpress.com